

Claims:

1. A stable pharmaceutical composition of omeprazole for oral administration which consists essentially of:
5 (a) a core of Omeprazole or a pharmaceutically equivalent salt, a filler and an alkaline material selected from the group consisting of lysine and arginine; and
(b) a single layer of coating on said core which
10 comprises a layer of an enteric coating agent applied from an organic solvent based system.

2. A pharmaceutical composition of omeprazole as defined in claim 1 wherein said core is further comprised essentially of a surface active agent, and a binder and said pharmaceutical composition is formed into a compressed tablet.
15

3. A pharmaceutical composition as defined in claim 1 wherein said core is further comprised essentially of a an inert core component, a surface active agent and a binder and said pharmaceutical composition is pelleted.
20

4. A pharmaceutical composition of omeprazole as defined in claim 2 wherein the acid resistant component is selected from the group consisting of cellulose acetate phthalate, hydroxypropylmethyl cellulose phthalate, polyvinyl acetate phthalate, carboxymethylcellulose, co-polymerized methacrylic acid/methacrylic acid methyl esters.
25

5. A pharmaceutical composition of omeprazole as defined in claim 3 wherein the acid resistant component is selected from the group consisting of cellulose acetate phthalate, hydroxypropylmethyl cellulose phthalate, polyvinyl acetate phthalate,
30
35

carboxymethylcellulose, co-polymerized methacrylic acid/methacrylic acid methyl esters.

6. A pharmaceutical composition of omeprazole as
5 defined in claim 1 wherein the enteric coating agent
also includes an inert processing aid.

7. A pharmaceutical composition of omeprazole as
defined in claim 1 wherein the enteric coating agent
10 around the core includes from 5 to 55wt% by weight of
the coating of an inert processing aid.

8. A pharmaceutical composition of omeprazole as
defined in claim 1 which includes a sodium lauryl
15 sulfate as the surface active agent. *1/2 anhydrous basis*

9. A pharmaceutical dosage formulation which consists
essentially of:

(a) a tablet core comprising omeprazole, a binder, an
20 alkaline agent selected from the group consisting of
arginine or lysine, a filler; and
(b) an enteric coating agent around said core, said
enteric coating comprising hydroxypropylmethyl
cellulose phthalate and talc.

25 *page 6x*
⑩ 10. A pharmaceutical composition as defined in claim 3
wherein the core contains a non-pariel sugar seed.

11. A pelleted pharmaceutical dosage formulation which
30 consists essentially of:

(a) a core comprising a non-pariel sugar seed coated
with drug layer composition comprising omeprazole,
a binder, an alkaline agent selected from the list
35 consisting of arginine and lysine, a filler and a
surface active agent; and
(b) an enteric coating agent around said core, said

enteric coating comprising hydroxypropylmethyl cellulose phthalate and talc which is applied from an organic solvent based system.

09263831 "0211031